Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazocin Intervention Study
NCT00478855Phase 4Completed
- Sponsor
- Pfizer
- Start
- Sep 2006
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, open-label trial of piperacillin + tazobactam in bacterial infection (2 arms), sponsored by Pfizer. Primary endpoint: Acquisition rate of ESBL producing E. coli or K. pneumoniae. Started Sep 2006; status: completed.
02
Drugs
piperacillin + tazobactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT00478855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00478855.